Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report
Abstract Background Hypereosinophilic syndrome is a group of disorders characterized by organ dysfunction caused by hypereosinophilia, which frequently leads to thromboembolic complications with potentially fatal outcomes. Interleukin-5, a key cytokine that promotes the differentiation and activatio...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-05-01
|
| Series: | Allergy, Asthma & Clinical Immunology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s13223-025-00967-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850154681159909376 |
|---|---|
| author | Daiki Nagira Satoshi Miyamoto Taishiro Mizukoshi Atsushi Yanagisawa Atsushi Funauchi Kensuke Kanaoka Hanako Yoshimura Tatsunori Jo Masayoshi Higashiguchi Yujiro Naito Takayuki Shiroyama Satoshi Tetsumoto Haruhiko Hirata Yoshito Takeda Atsushi Kumanogoh |
| author_facet | Daiki Nagira Satoshi Miyamoto Taishiro Mizukoshi Atsushi Yanagisawa Atsushi Funauchi Kensuke Kanaoka Hanako Yoshimura Tatsunori Jo Masayoshi Higashiguchi Yujiro Naito Takayuki Shiroyama Satoshi Tetsumoto Haruhiko Hirata Yoshito Takeda Atsushi Kumanogoh |
| author_sort | Daiki Nagira |
| collection | DOAJ |
| description | Abstract Background Hypereosinophilic syndrome is a group of disorders characterized by organ dysfunction caused by hypereosinophilia, which frequently leads to thromboembolic complications with potentially fatal outcomes. Interleukin-5, a key cytokine that promotes the differentiation and activation of eosinophils, has been identified as a therapeutic target. Anti-interleukin-5 antibody therapy has demonstrated efficacy in reducing eosinophil counts and enabling steroid dose tapering in patients with hypereosinophilic syndrome. This report describes the case of a patient with severe thromboembolism associated with hypereosinophilic syndrome during the acute phase who was successfully treated with benralizumab, an anti-interleukin-5 receptor alpha antibody. Case presentation A 22-year-old woman presented with a persistent cough and was diagnosed with eosinophilic pneumonia and portal vein thrombosis. Although eosinophilic pneumonia improved with corticosteroid therapy, thrombotic complications worsened despite additional anticoagulant treatment. The administration of benralizumab led to marked improvement in thrombosis, resulting in clinical recovery. Conclusions This case suggests that the early administration of anti-interleukin-5 receptor antibody therapy may be a valuable treatment option for refractory thrombosis. |
| format | Article |
| id | doaj-art-26b853baef574c8ea39895085a323335 |
| institution | OA Journals |
| issn | 1710-1492 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | BMC |
| record_format | Article |
| series | Allergy, Asthma & Clinical Immunology |
| spelling | doaj-art-26b853baef574c8ea39895085a3233352025-08-20T02:25:13ZengBMCAllergy, Asthma & Clinical Immunology1710-14922025-05-012111610.1186/s13223-025-00967-2Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case reportDaiki Nagira0Satoshi Miyamoto1Taishiro Mizukoshi2Atsushi Yanagisawa3Atsushi Funauchi4Kensuke Kanaoka5Hanako Yoshimura6Tatsunori Jo7Masayoshi Higashiguchi8Yujiro Naito9Takayuki Shiroyama10Satoshi Tetsumoto11Haruhiko Hirata12Yoshito Takeda13Atsushi Kumanogoh14Department of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityDepartment of Respiratory Medicine and Clinical Immunology, Municipal HospitalDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityDepartment of Respiratory Medicine and Clinical Immunology, Municipal HospitalDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityDepartment of Respiratory Medicine and Clinical Immunology, Municipal HospitalDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityDepartment of Respiratory Medicine and Clinical Immunology, Graduate School of Medicine, Osaka UniversityAbstract Background Hypereosinophilic syndrome is a group of disorders characterized by organ dysfunction caused by hypereosinophilia, which frequently leads to thromboembolic complications with potentially fatal outcomes. Interleukin-5, a key cytokine that promotes the differentiation and activation of eosinophils, has been identified as a therapeutic target. Anti-interleukin-5 antibody therapy has demonstrated efficacy in reducing eosinophil counts and enabling steroid dose tapering in patients with hypereosinophilic syndrome. This report describes the case of a patient with severe thromboembolism associated with hypereosinophilic syndrome during the acute phase who was successfully treated with benralizumab, an anti-interleukin-5 receptor alpha antibody. Case presentation A 22-year-old woman presented with a persistent cough and was diagnosed with eosinophilic pneumonia and portal vein thrombosis. Although eosinophilic pneumonia improved with corticosteroid therapy, thrombotic complications worsened despite additional anticoagulant treatment. The administration of benralizumab led to marked improvement in thrombosis, resulting in clinical recovery. Conclusions This case suggests that the early administration of anti-interleukin-5 receptor antibody therapy may be a valuable treatment option for refractory thrombosis.https://doi.org/10.1186/s13223-025-00967-2Hypereosinophilic syndrome (HES)ThromboembolismAnticoagulant therapySteroidInterleukin-5 receptor (IL-5 receptor)Benralizumab |
| spellingShingle | Daiki Nagira Satoshi Miyamoto Taishiro Mizukoshi Atsushi Yanagisawa Atsushi Funauchi Kensuke Kanaoka Hanako Yoshimura Tatsunori Jo Masayoshi Higashiguchi Yujiro Naito Takayuki Shiroyama Satoshi Tetsumoto Haruhiko Hirata Yoshito Takeda Atsushi Kumanogoh Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report Allergy, Asthma & Clinical Immunology Hypereosinophilic syndrome (HES) Thromboembolism Anticoagulant therapy Steroid Interleukin-5 receptor (IL-5 receptor) Benralizumab |
| title | Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report |
| title_full | Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report |
| title_fullStr | Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report |
| title_full_unstemmed | Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report |
| title_short | Benralizumab for acute thromboembolism in hypereosinophilic syndrome: a case report |
| title_sort | benralizumab for acute thromboembolism in hypereosinophilic syndrome a case report |
| topic | Hypereosinophilic syndrome (HES) Thromboembolism Anticoagulant therapy Steroid Interleukin-5 receptor (IL-5 receptor) Benralizumab |
| url | https://doi.org/10.1186/s13223-025-00967-2 |
| work_keys_str_mv | AT daikinagira benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT satoshimiyamoto benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT taishiromizukoshi benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT atsushiyanagisawa benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT atsushifunauchi benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT kensukekanaoka benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT hanakoyoshimura benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT tatsunorijo benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT masayoshihigashiguchi benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT yujironaito benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT takayukishiroyama benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT satoshitetsumoto benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT haruhikohirata benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT yoshitotakeda benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport AT atsushikumanogoh benralizumabforacutethromboembolisminhypereosinophilicsyndromeacasereport |